Новости портфельных компаний

  • 25 Июня 2013

    ReVision Optics: European study shows positive results for inlay in emmetropic presbyopic patients

    ReVision Optics: European study shows positive results for inlay in emmetropic presbyopic patients

    Results of the EuroKLEAR multicenter showed the safety and efficacy of the ReVision Optics Raindrop aspheric corneal inlay in emmetropic presbyopic patients.

  • 04 Февраля 2013

    Nanotechnology Didn't Shrink and Disappear; In Fact, It's Everywhere

    Nick Rockel, Institutional Investor

    Nanotechology, which involves controlling matter at the molecular and atomic levels, was a much-hyped investment theme a decade ago. It’s since become widely used in commercial products ranging from solar panels to semiconductors, but investing in nanotech requires patience.

  • 01 Февраля 2013

    Andrew Patterson meets a kiwi bio-tech company which has raised $74 million developing a therapeutic drug here for international markets

    Andrew Patterson meets a kiwi bio-tech company which has raised $74 million developing a therapeutic drug here for international markets

    Tracey Sunderland, COO, Coda Therapeutics Inc: “We think we’ve got something that has the potential to be a real game changer in this space particularly due to the fact that there are no therapeutic compounds on the market currently.”

  • 09 Января 2013

    San Diego Life Sciences Roundup: Trius, CoDa, Zacharon, & More

    Bruce V. Bigelow, Xconomy

    The annual International CES in Las Vegas again featured a Digital Health Summit, which included a number of San Diego-based startups. Rick Valencia of Qualcomm Life posted an interesting blog here, and an end-of-year report from Rock Health showed that investments in digital health startups increased more than 44 percent in 2012, to $1.4 billion from $968 million in 2011.

  • 07 Января 2013

    Marinus Pharmaceuticals Adds $21M Series C

    Marinus Pharmaceuticals Adds $21M Series C

    Marinus Pharmaceuticals, Inc. is pleased to announce $21 million in new Series C financing from U.S. venture capital firm Domain Associates, LLC, Rusnano subsidiary RusnanoMedInvest (RMI), and co-investors.

  • 20 Декабря 2012

    Regado Biosciences, Inc. secures $51 million series e financing

    Regado Biosciences, Inc. secures $51 million series e financing

    Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced it has secured a landmark $51 million Series E financing. New Investor Leads Round to Fund Phase 3 Development of REG1

  • 20 Декабря 2012

    Lithera, Inc. Completes $20.6 Million Equity Financing

    Lithera, Inc. Completes $20.6 Million Equity Financing

    Lithera, Inc. today announced investment of $20.6 million in preferred stock equity financing. The investment was led by RusnanoMedInvest (“RMI” a subsidiary of RUSNANO) made in connection with a joint investment collaboration with Domain Associates.

  • 24 Июля 2012

    CoDa Therapeutics Completes $49 Million Fund Raising

    CoDa Therapeutics Completes $49 Million Fund Raising

    CoDa Therapeutics, Inc. announced today that it raised an additional NZ$24.5M from Russian investment firm RusnanoMedInvest (“RMI”). This brings the company’s total Series B Round to nearly NZ$49 million following a first close late last year.

  • 06 Октября 2011

    Square 1 Announces $6 Million Credit Facility to CoDa Therapeutics, Inc.

    Square 1 Bank, the exclusive banking partner to entrepreneurs and the venture capital community, is pleased to partner with CoDa Therapeutics, Inc. in providing a $6 million term loan.

  • 29 Апреля 2011

    Marinus Pharmaceuticals Issued Patent for Ganaxolone

    Marinus Pharmaceuticals Issued Patent for Ganaxolone

    Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the company Patent Number 7,858,609 entitled, "Solid ganaxolone formulations and methods for the making and use thereof." The patent describes a novel class of small molecules to improve stability and bioavailability of nanoparticulate formulations of ganaxolone and will provide coverage until the end of 2026.  

Все Портфель

Медиа центр

  • НоваМедика успешно завершила клинические исследования первого препарата собственной разработки

    НоваМедика успешно завершила клинические исследования первого препарата собственной разработки

    Российская фармацевтическая компания «НоваМедика» (портфельная компания РОСНАНО) успешно завершила клинические исследования первого препарата, разработанного собственным R&D-подразделением. Новый лекарственный препарат – гель для лечения и облегчения симптоматики геморроя, основанный на уникальном механизме действия, который не используется в присутствующих сейчас на рынке продуктах. Старт продаж препарата планируется в конце 2017 года под торговым наименованием Фиссарио.

Перейти в медиа-центр